Omeros Corporation (NASDAQ:OMER) announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepted for presentation at the 2017 Tandem Meeting of the American Society of Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research in Orlando, Florida.
OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). In addition to its Phase 2 clinical program in TMAs, OMS721 is currently in a Phase 3 program for patients suffering from atypical hemolytic uremic syndrome and in a Phase 2 program for renal diseases, including immunoglobulin A (IgA) nephropathy and membranous nephropathy.
The title of the abstract is “Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA),” and will be presented on Saturday, February 25, by Dr. Samer Khaled, M.D., Assistant Clinical Professor of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte California and OMS721 clinical investigator. (Original Source)
Shares of Omeros closed yesterday at $11.11. OMER has a 1-year high of $16.80 and a 1-year low of $7.20. The stock’s 50-day moving average is $7.56 and its 200-day moving average is $10.97.
On the ratings front, Omeros has been the subject of a number of recent research reports. In a report issued on November 17, WBB analyst Stephen Brozak reiterated a Buy rating on OMER, with a price target of $75, which represents a potential upside of 575% from where the stock is currently trading. Separately, on November 10, Cantor Fitzgerald’s Elemer Piros reiterated a Buy rating on the stock and has a price target of $21.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Stephen Brozak and Elemer Piros have a yearly average return of 17.6% and 3.7% respectively. Brozak has a success rate of 47% and is ranked #450 out of 4262 analysts, while Piros has a success rate of 42% and is ranked #1240.
Sentiment on the street is mostly bullish on OMER stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $50.67, which implies an upside of 356% from current levels.
Omeros Corp. operates as a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.